学校法人順天堂　研究者情報データベース:::研究業績詳細:::

HOME　＞　研究業績詳細

研究業績詳細

安田肇（ヤスダハジメ）

研究テーマ	ビタミンB6欠乏症と血液疾患、悪性リンパ腫
研究業績（論文）	1. Yasuda H, Hoshino Y, Ando J, et al. Vitamin B6 Deficiency Polyneuropathy and Dermatitis. Am J Med 2023; 136(1): e10-e1. 2. Yasuda H, Ando J, Yoshida S, Ota Y, Komatsu N, Ando M. Diffuse Large B-cell Lymphoma with Adrenal Involvement Presenting as Other Iatrogenic Immunodeficiency-associated Lymphoproliferative Disorders: Sustained Remission with Methotrexate Termination Alone in Two Cases. Intern Med 2023; 62(4): 601-4. 3. Morishita S, Hashimoto Y, Furuya C, et al. Non-driver gene mutation analysis in a large cohort of polycythemia vera and essential thrombocythemia. Eur J Haematol 2023; 110(2): 131-6. 4. Mori Y, Araki M, Morishita S, et al. Clinical features of acquired erythrocytosis: Low levels of serum erythropoietin in a subset of non-neoplastic erythrocytosis patients. Cancer Med 2023; 12(2): 1079-89. 5. Yasuda H, Tomizawa Y, Harada S, et al. Anti-myelin-associated-glycoprotein neuropathy successfully treated with tirabrutinib. Heliyon 2022; 8(10): e10928. 6. Yasuda H, Komatsu N, Ando J, Ando M. Hodgkin Lymphoma on Hemodialysis: A Review of Treatment and Recommendations. Clin Lymphoma Myeloma Leuk 2022; 22(11): 805-11. 7. Yasuda H, Hatano T, Honda T, et al. Vitamin B6 Deficiency Anemia Attributed to Levodopa/Carbidopa Intestinal Gel Therapy for Parkinson's Disease: A Diagnostic Pitfall for Myelodysplastic Syndrome with Ring Sideroblasts. Intern Med 2022. 8. Yasuda H, Furukawa Y, Nishioka K, et al. Vitamin B6 deficiency as a cause of polyneuropathy in POEMS syndrome: rapid recovery with supplementation in two cases. Hematology 2022; 27(1): 463-8. 9. Watanabe N, Takaku T, Tsukune Y, et al. Bosutinib-induced lung injury: a report of two cases and literature review. Int J Hematol 2022; 115(6): 902-5. 10. Uchimura A, Yasuda H, Ando J, et al. Hodgkin Lymphoma on Hemodialysis Successfully Treated with Extended Courses of Brentuximab Vedotin. Case Rep Oncol 2022; 15(1): 263-6. 11. Misawa K, Yasuda H, Matsuda H, et al. Development of Acute Adult T-cell Leukemia Following PD-1 Blockade Therapy for Lung Cancer. Intern Med 2022; 61(22): 3421-4. 12. Misawa K, Yasuda H, Koyama D, et al. Adult paroxysmal cold hemoglobinuria following mRNA COVID-19 vaccination. EJHaem 2022; 3(3): 992-5. 13. Inano T, Yasuda H, Tsukune Y, et al. Abnormal Exacerbation of Moderately Differentiated Gastric Adenocarcinoma in a Patient with TAFRO Syndrome: An Impaired Tumor Immunity? Case Rep Oncol 2022; 15(1): 7-11. 14. Iizuka K, Morishita S, Nishizaki Y, et al. von Willebrand factor activity levels are influenced by driver mutation status in polycythemia vera and essential thrombocythemia patients with well-controlled platelet counts. Eur J Haematol 2022; 109(6): 779-86. 15. Baba T, Hashimoto Y, Yasuda H, et al. Validation and reliability of current guidelines for the treatment of essential thrombocythemia under real-world clinical settings in Japan. Hematology 2022; 27(1): 157-66. 16. Yasuda H, Yasuda M, Komatsu N. Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: A comprehensive review. Cancer Sci 2021; 112(7): 2607-24. 17. Yasuda H, Tsukune Y, Inano T, Mori Y, Ota Y, Komatsu N. Successful Long-Term Ibrutinib Treatment in a Hemodialysis Patient With Leukemic Nonnodal Mantle Cell Lymphoma. Clin Lymphoma Myeloma Leuk 2021; 21(2): e176-e8. 18. Yasuda H, Morishita S, Mori Y, et al.JAK2/CALR/SF3B1 triple-mutated　myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis evolving to myelofibrosis and SF3B1 single-mutated acute myeloid leukemia: Evidence of a pre-JAK2 clone. Leuk Res 2021; 100: 106496. 19. Yasuda H, Mori Y, Chiba A, et al. Resolution of One-Year Persisting COVID-19 Pneumonia and Development of Immune Thrombocytopenia in a Follicular Lymphoma Patient With Preceding Rituximab Maintenance Therapy: A follow-up Report and Literature Review of Cases With Prolonged Infections. Clin Lymphoma Myeloma Leuk 2021; 21(10): e810–e816. 20. Sano M, Iseki T, Sasaki M, et al. Improvement in the Symptoms and VEGF Levels after Resection of an Extrame Dullary Spinal Tumor and Additional Chemotherapy in a Patient with Multiple Myeloma Complicated with POEMS Syndrome. Intern Med 2021; 60(22): 3625-30. 21. Morishita S, Yasuda H, Yamawaki S, et al. CREB3L1 overexpression as a potential diagnostic marker of Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Sci 2021; 112(2): 884-92. 22. Edahiro Y, Yasuda H, Gotoh A, et al. Interferon therapy for pregnant patients with essential thrombocythemia in Japan. Int J Hematol 2021; 113(1): 106-11. 23. Ando J, Ueno Y, Yasuda H, et al. Radiation-Induced Myopathy Developing in a Hodgkin Lymphoma Patient: An Autopsy Case with Systemic Muscle Sampling. Case Rep Oncol 2021; 14(1): 338-42. 24. Yasuda H, Tsukune Y, Watanabe N, et al. Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma. Clin Lymphoma Myeloma Leuk 2020; 20(11): 774-6. 25. Edahiro Y, Yasuda H, Ando K, Komatsu N. Self-limiting pregnancy-associated pure red cell aplasia developing in two consecutive pregnancies: case report and literature review. Int J Hematol 2020; 111(4): 579-84. 26. Yasuda H, Tsutsui M, Ando J, et al. Vitamin B6 deficiency is prevalent in primary and secondary myelofibrosis patients. Int J Hematol 2019; 110(5): 543-9. 27. Tsutsui M, Yasuda H, Ota Y, Komatsu N. Splenic Marginal Zone Lymphoma with Prominent Myelofibrosis Mimicking Triple-Negative Primary Myelofibrosis. Case Rep Oncol 2019; 12(3): 834-7. 28. Inano T, Araki M, Morishita S, et al. JAK2 exon 12 mutation in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Not an exclusive mutation to polycythaemia vera. Br J Haematol 2019; 187(1): e27-e31. 29. Fukuda Y, Araki M, Yamamoto K, et al. Evidence for prevention of renal dysfunction associated with primary myelofibrosis by cytoreductive therapy. Haematologica 2019; 104(11): e506-e9. 30. Yasuda H, Tsutsui M, Ota Y, Tanaka M, Komatsu N. Indolent T-lymphoblastic proliferation concomitant with acinic cell carcinoma mimicking T-lymphoblastic lymphoma: case report and literature review. Histopathology 2018; 72(5): 862-6. 31. Ochiai T, Yasuda H, Araki M, et al. The 2014 BCSH criteria and the 2016 WHO criteria for essential thrombocythemia: A comparison in a large-scale cohort. Eur J Haematol 2018; 100(6): 544-9. 32. Misawa K, Yasuda H, Araki M, et al. Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms. Int J Hematol 2018; 107(6): 673-80. 33. Watanabe N, Yasuda H, Morishita S, et al. Richter's Syndrome with Hypercalcemia Induced by Tumor-Associated Production of Parathyroid Hormone-Related Peptide. Case Rep Oncol 2017; 10(1): 123-6. 34. Misawa K, Yasuda H, Araki M, et al. The 2016 WHO diagnostic criteria for polycythemia vera renders an accurate diagnosis to a broader range of patients including masked polycythemia vera: Comparison with the 2008 WHO diagnostic criteria. Am J Hematol 2017; 92(7): E128-e30. 35. Ando J, Masuda A, Iizuka K, et al. Factor XI deficiency as a result of a novel Tyr347Stop nonsense mutation in an elderly Japanese woman. Geriatr Gerontol Int 2017; 17(6): 1029-31. 36. Yasuda H, Tsutsui M, Ota Y, et al. Blastic plasmacytoid dendritic cell neoplasm accompanied by autoimmune hemolytic anemia achieving complete remission with hydroxyurea and steroids. Geriatr Gerontol Int 2016; 16(3): 396-8. 37. Edahiro Y, Ichikawa K, Suzuki H, Yasuda H, Koike M, Komatsu N. Successful perioperative management of factor XI deficiency with administration of fresh-frozen plasma in a subdural hematoma patient. Geriatr Gerontol Int 2016; 16(1): 143-4. 38. Yasuda H, Tsutsui M, Tanaka M, et al. Accurate flow cytometric gating of the large lymphocyte region is a powerful screening method for detecting hairy cell leukemia presenting with a low tumor burden. Intern Med 2015; 54(10): 1287-9. 39. Yasuda H, Fujiwara N, Ishizaki Y, Komatsu N. Anemia attributed to vitamin B6 deficiency in post-pancreaticoduodenectomy patients. Pancreatology 2015; 15(1): 81-3. 40. Watanabe N, Yasuda H, Aota Y, et al. Reactivation of hepatitis B virus during treatment with hydroxyurea in an elderly patient with essential thrombocythemia. Geriatr Gerontol Int 2015; 15(6): 812-3. 41. Yasuda H, Takaku T, Tomomatsu J, Hosone M, Tanaka H, Komatsu N. Spontaneous regression of cutaneous blastic plasmacytoid dendritic cell neoplasm followed by acute monocytic leukemia evolving from myelodysplastic syndrome. Intern Med 2014; 53(23): 2717-20. 42. Aritaka N, Ichikawa K, Nakamura H, et al. Attainment of a stringent complete response in multiple myeloma with thalidomide monotherapy. Intern Med 2012; 51(19): 2781-3. 43. Yasuda H, Aritaka N, Ando J, Hirama M, Komatsu N, Hirano T. Chronic myelogenous leukemia with mild basophilia as the predominant manifestation at presentation. Intern Med 2011; 50(5): 501-2. 44. Yasuda H, Ando J, Sato E, et al. Successful treatment of extramedullary tumors with low-dose thalidomide in patients with multiple myeloma. Intern Med 2010; 49(23): 2617-20. 45. Yasuda H, Ando J, Matsumoto T, et al. Intravascular large B cell lymphoma with hepatic portal vein, splenic vein and mesenteric vein tumour embolism. Histopathology 2010; 57(4): 648-50. 46. Tsutsui M, Yasuda H, Suto H, et al. Frequent STAT3 activation is associated with Mcl-1 expression in nasal NK-cell lymphoma. International Journal of Laboratory Hematology 2010; 32(4): 419-26. 47. Tsukune Y, Isobe Y, Yasuda H, et al. Activity and safety of combination chemotherapy with methotrexate, ifosfamide, l-asparaginase and dexamethasone (MILD) for refractory lymphoid malignancies: a pilot study. Eur J Haematol 2010; 84(4): 310-5. 48. Suto H, Yasuda H, Isobe Y, et al. Suppression of eIF4E expression by L-Asparaginase. Acta Haematol 2010; 123(4): 215-9. 49. Yasuda H, Sugimoto K, Imai H, et al. Expression levels of apoptosis-related proteins and Ki-67 in nasal NK / T-cell lymphoma. Eur J Haematol 2009; 82(1): 39-45. 50. Imai H, Sugimoto K, Isobe Y, et al. Absence of tumor-specific over-expression of Polo-like kinase 1 (Plk1) in major non-Hodgkin lymphoma and relatively low expression of Plk1 in nasal NK/T cell lymphoma. Int J Hematol 2009; 89(5): 673-8. 51. Sasaki M, Sugimoto K, Kawahara S, Yasuda H, Suto H, Oshimi K. Rapid elimination of circulating leukemia cells with a small dose of alemtuzumab in refractory aggressive NK-cell leukemia. Eur J Haematol 2007; 78(6): 545.

研究テーマ

ビタミンB6欠乏症と血液疾患、悪性リンパ腫

研究業績（論文）

1. Yasuda H, Hoshino Y, Ando J, et al. Vitamin B6 Deficiency Polyneuropathy and Dermatitis. Am J Med 2023; 136(1): e10-e1.
2. Yasuda H, Ando J, Yoshida S, Ota Y, Komatsu N, Ando M. Diffuse Large B-cell Lymphoma with Adrenal Involvement Presenting as Other Iatrogenic Immunodeficiency-associated Lymphoproliferative Disorders: Sustained Remission with Methotrexate Termination Alone in Two Cases. Intern Med 2023; 62(4): 601-4.
3. Morishita S, Hashimoto Y, Furuya C, et al. Non-driver gene mutation analysis in a large cohort of polycythemia vera and essential thrombocythemia. Eur J Haematol 2023; 110(2): 131-6.
4. Mori Y, Araki M, Morishita S, et al. Clinical features of acquired erythrocytosis: Low levels of serum erythropoietin in a subset of non-neoplastic erythrocytosis patients. Cancer Med 2023; 12(2): 1079-89.
5. Yasuda H, Tomizawa Y, Harada S, et al. Anti-myelin-associated-glycoprotein neuropathy successfully treated with tirabrutinib. Heliyon 2022; 8(10): e10928.
6. Yasuda H, Komatsu N, Ando J, Ando M. Hodgkin Lymphoma on Hemodialysis: A Review of Treatment and Recommendations. Clin Lymphoma Myeloma Leuk 2022; 22(11): 805-11.
7. Yasuda H, Hatano T, Honda T, et al. Vitamin B6 Deficiency Anemia Attributed to Levodopa/Carbidopa Intestinal Gel Therapy for Parkinson's Disease: A Diagnostic Pitfall for Myelodysplastic Syndrome with Ring Sideroblasts. Intern Med 2022.
8. Yasuda H, Furukawa Y, Nishioka K, et al. Vitamin B6 deficiency as a cause of polyneuropathy in POEMS syndrome: rapid recovery with supplementation in two cases. Hematology 2022; 27(1): 463-8.
9. Watanabe N, Takaku T, Tsukune Y, et al. Bosutinib-induced lung injury: a report of two cases and literature review. Int J Hematol 2022; 115(6): 902-5.
10. Uchimura A, Yasuda H, Ando J, et al. Hodgkin Lymphoma on Hemodialysis Successfully Treated with Extended Courses of Brentuximab Vedotin. Case Rep Oncol 2022; 15(1): 263-6.
11. Misawa K, Yasuda H, Matsuda H, et al. Development of Acute Adult T-cell Leukemia Following PD-1 Blockade Therapy for Lung Cancer. Intern Med 2022; 61(22): 3421-4.
12. Misawa K, Yasuda H, Koyama D, et al. Adult paroxysmal cold hemoglobinuria following mRNA COVID-19 vaccination. EJHaem 2022; 3(3): 992-5.
13. Inano T, Yasuda H, Tsukune Y, et al. Abnormal Exacerbation of Moderately Differentiated Gastric Adenocarcinoma in a Patient with TAFRO Syndrome: An Impaired Tumor Immunity? Case Rep Oncol 2022; 15(1): 7-11.
14. Iizuka K, Morishita S, Nishizaki Y, et al. von Willebrand factor activity levels are influenced by driver mutation status in polycythemia vera and essential thrombocythemia patients with well-controlled platelet counts. Eur J Haematol 2022; 109(6): 779-86.
15. Baba T, Hashimoto Y, Yasuda H, et al. Validation and reliability of current guidelines for the treatment of essential thrombocythemia under real-world clinical settings in Japan. Hematology 2022; 27(1): 157-66.
16. Yasuda H, Yasuda M, Komatsu N. Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: A comprehensive review. Cancer Sci 2021; 112(7): 2607-24.
17. Yasuda H, Tsukune Y, Inano T, Mori Y, Ota Y, Komatsu N. Successful Long-Term Ibrutinib Treatment in a Hemodialysis Patient With Leukemic Nonnodal Mantle Cell Lymphoma. Clin Lymphoma Myeloma Leuk 2021; 21(2): e176-e8.
18. Yasuda H, Morishita S, Mori Y, et al.JAK2/CALR/SF3B1 triple-mutated　myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis evolving to myelofibrosis and SF3B1 single-mutated acute myeloid leukemia: Evidence of a pre-JAK2 clone. Leuk Res 2021; 100: 106496.
19. Yasuda H, Mori Y, Chiba A, et al. Resolution of One-Year Persisting COVID-19 Pneumonia and Development of Immune Thrombocytopenia in a Follicular Lymphoma Patient With Preceding Rituximab Maintenance Therapy: A follow-up Report and Literature Review of Cases With Prolonged Infections. Clin Lymphoma Myeloma Leuk 2021; 21(10): e810–e816.
20. Sano M, Iseki T, Sasaki M, et al. Improvement in the Symptoms and VEGF Levels after Resection of an Extrame Dullary Spinal Tumor and Additional Chemotherapy in a Patient with Multiple Myeloma Complicated with POEMS Syndrome. Intern Med 2021; 60(22): 3625-30.
21. Morishita S, Yasuda H, Yamawaki S, et al. CREB3L1 overexpression as a potential diagnostic marker of Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Sci 2021; 112(2): 884-92.
22. Edahiro Y, Yasuda H, Gotoh A, et al. Interferon therapy for pregnant patients with essential thrombocythemia in Japan. Int J Hematol 2021; 113(1): 106-11.
23. Ando J, Ueno Y, Yasuda H, et al. Radiation-Induced Myopathy Developing in a Hodgkin Lymphoma Patient: An Autopsy Case with Systemic Muscle Sampling. Case Rep Oncol 2021; 14(1): 338-42.
24. Yasuda H, Tsukune Y, Watanabe N, et al. Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma. Clin Lymphoma Myeloma Leuk 2020; 20(11): 774-6.
25. Edahiro Y, Yasuda H, Ando K, Komatsu N. Self-limiting pregnancy-associated pure red cell aplasia developing in two consecutive pregnancies: case report and literature review. Int J Hematol 2020; 111(4): 579-84.
26. Yasuda H, Tsutsui M, Ando J, et al. Vitamin B6 deficiency is prevalent in primary and secondary myelofibrosis patients. Int J Hematol 2019; 110(5): 543-9.
27. Tsutsui M, Yasuda H, Ota Y, Komatsu N. Splenic Marginal Zone Lymphoma with Prominent Myelofibrosis Mimicking Triple-Negative Primary Myelofibrosis. Case Rep Oncol 2019; 12(3): 834-7.
28. Inano T, Araki M, Morishita S, et al. JAK2 exon 12 mutation in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Not an exclusive mutation to polycythaemia vera. Br J Haematol 2019; 187(1): e27-e31.
29. Fukuda Y, Araki M, Yamamoto K, et al. Evidence for prevention of renal dysfunction associated with primary myelofibrosis by cytoreductive therapy. Haematologica 2019; 104(11): e506-e9.
30. Yasuda H, Tsutsui M, Ota Y, Tanaka M, Komatsu N. Indolent T-lymphoblastic proliferation concomitant with acinic cell carcinoma mimicking T-lymphoblastic lymphoma: case report and literature review. Histopathology 2018; 72(5): 862-6.
31. Ochiai T, Yasuda H, Araki M, et al. The 2014 BCSH criteria and the 2016 WHO criteria for essential thrombocythemia: A comparison in a large-scale cohort. Eur J Haematol 2018; 100(6): 544-9.
32. Misawa K, Yasuda H, Araki M, et al. Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms. Int J Hematol 2018; 107(6): 673-80.
33. Watanabe N, Yasuda H, Morishita S, et al. Richter's Syndrome with Hypercalcemia Induced by Tumor-Associated Production of Parathyroid Hormone-Related Peptide. Case Rep Oncol 2017; 10(1): 123-6.
34. Misawa K, Yasuda H, Araki M, et al. The 2016 WHO diagnostic criteria for polycythemia vera renders an accurate diagnosis to a broader range of patients including masked polycythemia vera: Comparison with the 2008 WHO diagnostic criteria. Am J Hematol 2017; 92(7): E128-e30.
35. Ando J, Masuda A, Iizuka K, et al. Factor XI deficiency as a result of a novel Tyr347Stop nonsense mutation in an elderly Japanese woman. Geriatr Gerontol Int 2017; 17(6): 1029-31.
36. Yasuda H, Tsutsui M, Ota Y, et al. Blastic plasmacytoid dendritic cell neoplasm accompanied by autoimmune hemolytic anemia achieving complete remission with hydroxyurea and steroids. Geriatr Gerontol Int 2016; 16(3): 396-8.
37. Edahiro Y, Ichikawa K, Suzuki H, Yasuda H, Koike M, Komatsu N. Successful perioperative management of factor XI deficiency with administration of fresh-frozen plasma in a subdural hematoma patient. Geriatr Gerontol Int 2016; 16(1): 143-4.
38. Yasuda H, Tsutsui M, Tanaka M, et al. Accurate flow cytometric gating of the large lymphocyte region is a powerful screening method for detecting hairy cell leukemia presenting with a low tumor burden. Intern Med 2015; 54(10): 1287-9.
39. Yasuda H, Fujiwara N, Ishizaki Y, Komatsu N. Anemia attributed to vitamin B6 deficiency in post-pancreaticoduodenectomy patients. Pancreatology 2015; 15(1): 81-3.
40. Watanabe N, Yasuda H, Aota Y, et al. Reactivation of hepatitis B virus during treatment with hydroxyurea in an elderly patient with essential thrombocythemia. Geriatr Gerontol Int 2015; 15(6): 812-3.
41. Yasuda H, Takaku T, Tomomatsu J, Hosone M, Tanaka H, Komatsu N. Spontaneous regression of cutaneous blastic plasmacytoid dendritic cell neoplasm followed by acute monocytic leukemia evolving from myelodysplastic syndrome. Intern Med 2014; 53(23): 2717-20.
42. Aritaka N, Ichikawa K, Nakamura H, et al. Attainment of a stringent complete response in multiple myeloma with thalidomide monotherapy. Intern Med 2012; 51(19): 2781-3.
43. Yasuda H, Aritaka N, Ando J, Hirama M, Komatsu N, Hirano T. Chronic myelogenous leukemia with mild basophilia as the predominant manifestation at presentation. Intern Med 2011; 50(5): 501-2.
44. Yasuda H, Ando J, Sato E, et al. Successful treatment of extramedullary tumors with low-dose thalidomide in patients with multiple myeloma. Intern Med 2010; 49(23): 2617-20.
45. Yasuda H, Ando J, Matsumoto T, et al. Intravascular large B cell lymphoma with hepatic portal vein, splenic vein and mesenteric vein tumour embolism. Histopathology 2010; 57(4): 648-50.
46. Tsutsui M, Yasuda H, Suto H, et al. Frequent STAT3 activation is associated with Mcl-1 expression in nasal NK-cell lymphoma. International Journal of Laboratory Hematology 2010; 32(4): 419-26.
47. Tsukune Y, Isobe Y, Yasuda H, et al. Activity and safety of combination chemotherapy with methotrexate, ifosfamide, l-asparaginase and dexamethasone (MILD) for refractory lymphoid malignancies: a pilot study. Eur J Haematol 2010; 84(4): 310-5.
48. Suto H, Yasuda H, Isobe Y, et al. Suppression of eIF4E expression by L-Asparaginase. Acta Haematol 2010; 123(4): 215-9.
49. Yasuda H, Sugimoto K, Imai H, et al. Expression levels of apoptosis-related proteins and Ki-67 in nasal NK / T-cell lymphoma. Eur J Haematol 2009; 82(1): 39-45.
50. Imai H, Sugimoto K, Isobe Y, et al. Absence of tumor-specific over-expression of Polo-like kinase 1 (Plk1) in major non-Hodgkin lymphoma and relatively low expression of Plk1 in nasal NK/T cell lymphoma. Int J Hematol 2009; 89(5): 673-8.
51. Sasaki M, Sugimoto K, Kawahara S, Yasuda H, Suto H, Oshimi K. Rapid elimination of circulating leukemia cells with a small dose of alemtuzumab in refractory aggressive NK-cell leukemia. Eur J Haematol 2007; 78(6): 545.

研究者

教育活動

【学校法人順天堂】研究者情報データベース

研究業績詳細

安田 肇（ヤスダ ハジメ）

安田肇（ヤスダハジメ）